Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD).
Ascendis Pharma A stock last closed at $225.98, down 1.32% from the previous day, and has increased 48.37% in one year. It has overperformed other stocks in the Biotechnology industry by 0.88 percentage points. Ascendis Pharma A stock is currently +82.15% from its 52-week low of $124.06, and -9.09% from its 52-week high of $248.58.
There are currently 61.38M shares of ASND outstanding. The market value of ASND is $13.87B. In the last 24 hours, 606,000 ASND shares were traded.
How to Buy Ascendis Pharma A Stock
Not sure how to invest in Ascendis Pharma A stock? Here's how.
Figure out where to buy Ascendis Pharma A stock: You need to decide on a stock brokerage, but don't worry - we've tried dozens of online stock brokerages and apps to help you choose where to buy Ascendis Pharma A stock.
Sign up for your brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've found.
Deposit money your brokerage account: Choose your method of payment and add your information.
Research Ascendis Pharma A stock: The Ascendis Pharma A ticker symbol is ASND. Is Ascendis Pharma A stock a good investment? Should you buy shares of ASND? How do ASND's underlying business fundamentals look? Do top analysts think Ascendis Pharma A is a good buy? Why has ASND's stock price moved recently? (Hint: Our stock market research website can help you understand if ASND is a good stock to buy).
Make your ASND trade: Decide if you will purchase ASND shares at the current market price or use a limit order to purchase ASND shares at a given price.
Get updates on your investment in ASND: Create a watchlist to keep track of your investment in Ascendis Pharma A shares.
Step 1: Figure out where to buy Ascendis Pharma A stock
You will need a brokerage account in order to access the NASDAQ market and buy ASND stock.
A brokerage account allows you to buy and sell a number of financial instruments, including stocks, bonds, mutual funds, and ETFs.
Our recommended brokerage: eToro
We believe that eToro is the best brokerage. eToro gives you:
You can invest in stocks with 0% commissions: Invest without paying trading commissions.
Buy fractional shares: Even if you can't afford a full share, you can still invest in the stock.
Access to global financial markets: From Technology to Energy, New York to Shanghai (for US users, only US stocks are available) — you can fill your portfolio with stocks from the world's top stock exchanges.
Social investing: eToro offers a community of more than 20 million users worldwide. Talk to, learn from, and copy the crypto trades of other investors.
Security: eToro is a regulated and licensed fintech leader.
Buy other assets: Such as ETFs and cryptos.
Get $10 towards your stock purchase by creating an account with eToro now. This offer is only for US users.
eToro securities trading is offered by eToro USA Securities, Inc. (“the BD”), member of FINRA and SIPC. Cryptocurrency is offered by eToro USA LLC (“the MSB”) (NMLS: 1769299) and is not FDIC or SIPC insured. Investing involves risk, and content is provided for educational purposes only, does not imply a recommendation, and is not a guarantee of future performance. https://www.wallstreetzen.com is not an affiliate and may be compensated if you access certain products or services offered by the MSB and/or the BD.
Step 2: Sign up for your brokerage account
Now that you've chosen the best brokerage, the next step is to fill out some personal info so you can buy ASND today.
eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
Step 4: Research Ascendis Pharma A stock
After you have selected the best place to buy Ascendis Pharma A stock, it's crucial to research their stock prior to buying, so you truly comprehend the risk as well as the upside.
Ascendis Pharma A shares quick numbers
ASND Price
$225.98
1w %
-6.1%
1y %
48.37%
5y %
53.73%
P/E
-51.08x
P/B
-72.41x
P/S
16.37x
PEG
N/A
Revenue
$847.21M
Earnings
-$268.28M
Fore. Rev. Growth
44.4%
Fore. Earn. Growth
N/A
Market Cap
$13.87B
Next Earnings
Apr 30, 2026
Next Dividend
N/A
ASND Due Diligence Checks
WallStreetZen was created to help everyday investors perform better fundamental analysis in minutes instead of hours.
There are more short-term assets than long-term liabilities on the ASND balance sheet.
There are more short-term assets than short-term liabilities on the ASND balance sheet.
Failed Financial Due Diligence Checks:
ASND earnings of -$7.02M is not enough to cover its interest payments.
ASND profit margin has gone up by 0.72 percentage points in the past year, but the company is still unprofitable.
Total ASND debt is still negative.
ASND debt to equity ratio of -9 is negative.
ASND's operating cash flow of $63.41M allows it to safely service it's debt of $1.33B.
Is it a good time to buy ASND stock, according to analysts?
Out of 11 Equities analysts who give forecasts on ASND, the consensus analyst rating on ASND is a Strong Buy
Please note that analyst ratings are not recommendations, nor are they financial advice.
Most Recent ASND Analyst Ratings
Derek Archila, a top 3% analyst from Wells Fargo maintains ASND with a strong buy rating and raises their ASND price target from $322.00 to $330.00, on Jan 20, 2026.
Wells Fargo's Derek Archila raised their price target on Ascendis Pharma A (NASDAQ: ASND) by 2.5% from $322 to $330 on 2026/01/20. The analyst maintained their Strong Buy rating on the stock.
Archila reported that a deep dive into their Healthcare sector coverage catalyzed their price target hike on Ascendis Pharma A.
Consistent with management's recent comments projecting €40M to €50M Q/Q sales growth, the analyst noted that management's €500M OCF guidance excluding CNP suggests €1.1B to €1.2B for Yorvipath.
Yaron Werber, a top 31% analyst from TD Cowen reiterates ASND with a strong buy rating and maintains their ASND price target from $325.00 to $325.00, on Jan 7, 2026.
Alex Thompson, a top 9% analyst from Stifel Nicolaus maintains ASND with a strong buy rating and raises their ASND price target from $254.00 to $256.00, on Dec 11, 2025.
Martin Auster, a top 21% analyst from Raymond James initiates coverage on ASND with a strong buy rating and announces their ASND price target of $271.00, on Oct 17, 2025.
Li Watsek, a top 42% analyst from Cantor Fitzgerald maintains ASND with a strong buy rating and raises their ASND price target from $203.00 to $254.00, on Oct 13, 2025.
Last year, ASND revenue was $847.21M. During the last 5 year, ASND's revenue has increased by 151.15% per year. This was faster than the Biotechnology industry average of 29.33%.
No, Ascendis Pharma A doesn't provide an income stream by paying out dividends.
What do other traders have to say about ASND?
One of the major reasons eToro is our favorite brokerage is because of its social trading community.
Click below to see what other investors have to say.
Step 5: Make your ASND trade
There are two primary order types:
Market order: A market order is an order to buy or sell a stock at the best price on the market. Market orders are generally fine for most investors.
Limit order: A limit order is an order to buy or sell a stock at a specific price (or better). If you want to be certain you're buying or selling at an exact price, place a limit order.
Press the Open button and eToro will execute your order.
If you want additional help investing in stocks on eToro, watch the how to video below:
How much does it cost to buy one Ascendis Pharma A share?
As of Mar 13, 2026, it costs $225.98 to buy one share of Ascendis Pharma A stock.
Remember, eToro's fractional share buying allows you to buy partial shares of stocks and ETFs. Even if you only have $100, you can buy 0.443 shares of ASND.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.